Cyrine Ben Fadhel

Global Ventures is an international venture capital firm, investing in founders and ideas across emerging markets. We back global-minded founders that are leading growth-stage companies and using technology to transform emerging markets and the world. The Global Ventures team is a diverse, collaborative, talented and curious group of professionals who, combined, have years of experience and expertise building and scaling companies.

Next Generation Anti-Infectives that Mimic Natural Human Antimicrobial Peptides Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented low molecular weight drug candidates that destroy SARS-CoV-2, the COVID virus, as well as other viruses and infectious pathogens (including fungal and bacterial pathogens). Maxwells first-in-class CLAROMER™ brand drug discovery platform mimics natural human immune system antimicrobial and antiviral peptides. Maxwell Biosciences has benefitted from over $35M of non-dilutive grants and awards from governments around the world to validate their science and technology, including studies by US Govt-funded labs confirming that Maxwells lead drug candidate has direct virucidal action against Herpes virus (HSV-1) and SARS-CoV-2, the COVID virus. Additionally, live mouse safety data at Texas A&M show Maxwells drugs benefit from a tissue-safe toxicology profiles, and live mouse studies from the Baylor College of Medicine show breakthrough fungicidal action with CLAROMER™ brand compounds against lethal fungal infections of the upper-respiratory tract. These findings support the expected safety and effectiveness of Maxwells “multi-asset, multi-target” anti-infectives drug platform. Maxwells drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics and a broad spectrum of evolving infectious pathogens. Maxwell is raising funds for advanced preclinical and human trials.

On-demand food delivery from dark kitchens. Pakistans first YC-backed consumer internet startup.

The future of finance in Africa is embedded, and Higa Capital is here to fuel its rise. Our mission is to back visionaries who are engineering the infrastructure for a financial revolution—one that eliminates barriers, empowers communities, and transforms lives. We invest in early-stage startups that are redefining financial access and inclusion by bringing financial services to where people already are.

Seedstars is a global organisation with a mission to impact peoples lives in emerging & frontier markets through technology and entrepreneurship. If you are interested in joining an exciting mission and work in a flexible environment where you are supported to do your best, then check out our careers page: seedstars.com/careers/

Global Ventures is an international venture capital firm, investing in founders and ideas across emerging markets. We back global-minded founders that are leading growth-stage companies and using technology to transform emerging markets and the world. The Global Ventures team is a diverse, collaborative, talented and curious group of professionals who, combined, have years of experience and expertise building and scaling companies.

Next Generation Anti-Infectives that Mimic Natural Human Antimicrobial Peptides Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented low molecular weight drug candidates that destroy SARS-CoV-2, the COVID virus, as well as other viruses and infectious pathogens (including fungal and bacterial pathogens). Maxwells first-in-class CLAROMER™ brand drug discovery platform mimics natural human immune system antimicrobial and antiviral peptides. Maxwell Biosciences has benefitted from over $35M of non-dilutive grants and awards from governments around the world to validate their science and technology, including studies by US Govt-funded labs confirming that Maxwells lead drug candidate has direct virucidal action against Herpes virus (HSV-1) and SARS-CoV-2, the COVID virus. Additionally, live mouse safety data at Texas A&M show Maxwells drugs benefit from a tissue-safe toxicology profiles, and live mouse studies from the Baylor College of Medicine show breakthrough fungicidal action with CLAROMER™ brand compounds against lethal fungal infections of the upper-respiratory tract. These findings support the expected safety and effectiveness of Maxwells “multi-asset, multi-target” anti-infectives drug platform. Maxwells drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics and a broad spectrum of evolving infectious pathogens. Maxwell is raising funds for advanced preclinical and human trials.

We invest in idea-stage and pre-seed fintechs globally, anchoring on founder-market fit. Our portfolio includes Pomelo, Simetrik, Sydecar, Stitch, Abhi and TripleA.